Vigil Neuroscience Press Release
ALSP Trial Update
Vigil Neuroscience have announced “Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP”
To read the press release: ALSP Press Release
